The SpeediCath Flex Set catheter is developed for people living with bladder and urinary problems.

The SpeediCath Flex Set catheter will help patients catheterise at home or away. Credit: Coloplast Group.

Danish medical device company Coloplast is set to launch its new SpeediCath Flex Set catheter in the US this month.

The new catheter is a gentle, all-in-one solution that has been developed for people living with bladder and urinary problems.

It features a no-touch dry sleeve as well as an omnidirectional tip, which can bend to follow the curves of the urethra.

The SpeediCath Flex Set has a soft-squeeze grip that safely guides the tip into the urethra without making contact.

It helps patients catheterise at home or away and also supports them in managing conditions and sustaining healthy lifestyles.

The company stated that all the SpeediCath catheters have Triple Action Coating Technology, which is intended to reduce the risk of urethral damage as well as urinary tract infections (UTIs).

It also noted that the Triple Action Coating Technology in the catheter is an option for people with spinal cord injuries (SCI).

RELATED: Neosoma, Inc., an Innovative Medical Technology Company Focused on Helping Clinicians Advance the Treatment of Brain Cancers, Announced its AI Solutions Connect to the Nuance Precision Imaging Network

Coloplast North America Chronic Care senior vice-president Manu Varma said: “With SpeediCath Flex Set, we are introducing an important solution for people living with SCI and many other health conditions.

“We are confident that its new innovative design will make a big difference to our users, improving their catheterisation routine in many ways.”

The company is offering the SpeediCath Flex Set as a catheter and bag solution, also known as a Closed System.

It said that the new all-in-one solution is available in standard and pocket sizes.

The new SpeediCath Flex is reclosable and features non-medical, practical packaging for safe hygiene handling and disposal.

In 2020, Coloplast acquired Nine Continents Medical, an implantable tibial nerve stimulation (ITNS) treatment developer, in a deal valued at $145m.

Are you Hiring?